A former NPR Moscow bureau chief, Michele Kelemen now covers the State Department. Her reports can be heard on all NPR News programs — from Morning Edition to All Things Considered.
For years doctors advised women against hormone therapy for women in the menopausal transition. Now everyone's talking about how great it is. Is it really a wonder drug that women should all be on?
Researchers warn betting on clinical trials could incentivize insider trading and interfere with drug development. But Kalshi and Polymarket say they provide valuable information to patients.
Deaths and close calls while fighting wildfires have strained an already on-edge workforce. They've also raised questions about policies and priorities amid an intense wildfire season.